Watchlist

Watchlist
ANI Pharmaceuticals, Inc. (ANIP)
ANI Pharmaceuticals, Inc. (ANIP)
Biotech Forum Daily Digest: Impacts Of Tax Reform
"Fame is a fickle food upon a shifting plate." - Emily Dickinson It has been a pretty wild ride in biotech land this week. The main biotech indices dropped over one percent on Tuesday, clawed back those losses on Wednesday, only to fall more than one percent in trading Thursday. In early g…
Biotech Forum Daily Digest: What Now For Recro Pharma?
"Critics! Appalled I ventured on the name. Those cutthroat bandits in the paths of fame." - Robert Burns Biotech had a decent but unspectacular holiday-shortened trading week, as sentiment was a bit more positive on the high beta parts of the market (the Russell 2000 was up 2% on the week)…
Ani Pharmaceuticals: Potential Buyout Gains Credence
The merger with Ani Pharmaceuticals (NASDAQ: ANIP ) and the subsequent reverse split left Biosante Pharmaceuticals shareholders with approximately 4,125,800 shares of Ani Pharmaceuticals (43% of the merged company) in June 2013. How much would a Biosante buyout have been in 2012, had Biosa…
Generics up on Mylan sales forecast and potential $3B investment in Teva by noted investor
Positive developments in Mylan N.V. ( MYL +4.5% ) and Teva Pharmaceutical Industries ( TEVA +7.7% ) have apparently stoked buying in the generic drug space. More news on: Mylan Inc, Teva Pharmaceutical Industries Limited, ANI Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the…
ANI Pharmaceuticals' (ANIP) CEO Arthur Przybyl on Q3 2017 Results - Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q3 2017 Earnings Conference Call November 02, 2017, 10:30 ET Executives Arthur Przybyl - CEO, President and Director Stephen Carey - CFO and VP of Finance Analysts Elliot Wilbur - Raymond James & Associates Dewey Steadman - Canaccord G…
ANI Pharmaceuticals beats by $0.12, revenue in-line
ANI Pharmaceuticals (NASDAQ: ANIP ): Q3 EPS of $1.11 beats by $0.12 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more …
ANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year Guidance
BAUDETTE, Minn. , Nov. 2, 2017 /PRNewswire/ -- For the third quarter 2017: Net revenues of $48.2 million , an increase of 25% as compared to the same period in 2016 GAAP net income of $4.7 million and diluted GAAP earnings per share of $0.40 Adjusted non-GA…
Notable earnings before Thursday's open
AAON , ABC , ACIW , ADNT , ADP , AER , AES , AMAG , AMCX , AME , AN , ANIP , APA , APLP , ARCC , AROC , ARW , AVP , AYR , BABA , BCE , BDX , BIOS , BLL , BTE , CBB , CBZ , CCOI , CHD , CHK , CHSP , CI , CIM , CNNX , CNQ , CNSL , CRCM , CRK , CVE , CYB…
Mylan leads generic drug maker selloff on expanded Fed probe into generic drug pricing; shares down 8%
Some generic drug makers are under pressure in apparent response the federal government's decision to expand its investigation into alleged collusion to fix drug prices. More news on: Mylan Inc, Amphastar, ANI Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more…
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2017 Financial Results
BAUDETTE, Minn. , Oct. 26, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2017 financial results on Thursday, November 2, 2017 , before the opening of the U.S. financial markets. The earni…
Biotech Forum Daily Digest: Aratana Therapeutics Back In The Spotlight
"Never compete with someone who has nothing to lose." - Baltasar Gracian It will be interesting to see if the biotech sector can bounce back this week after a downturn last week. Investor sentiment seemed to shift into negative late last week. Some of the decline was probably attributable …
ANI Pharmaceuticals, Inc. (ANIP)